To access this material please log in or register

Register Authorize

Influence of atorvastatin on lipid transport function of blood, markers of insulin resistance and inflammation indices in patients with myocardial infarction in dynamics during hospitalisation

Silonova A. A., Barbarash O. L., Akbasheva O. E., Palicheva E. I., Karetnikova V. N., Uchasova E. G., Kvitkova L. V., Kashtalap V. V., Gruzdeva O. V.

Keywords: adipokines, atorvastatin, inflammation, insulin resistance, myocardial infarction, pleiotropy

DOI: 10.18087/rhj.2012.6.1751

Relevance. High mortality rate and incapacitation after MI indicate necessity of search of adequate therapeutic strategies. Atorvastatin is one of the promising drugs. Objective. Study influence of atorvastatin on lipid parameters, adipokine status, insulin resistance (IR) markers and inflammation indices patients with MI in dynamics of hospital period. Materials and methods. 22 patients with ST-elevated MI were enrolled to the study, who received atorvastatin therapy, and 22 patients receiving only standard therapy. On days 1 and 12 after MI, cholesterol, LDL cholesterol, VLDL cholesterol, HDL cholesterol, apolipoprotein А (Apo-А), apolipoprotein В (Apo-В), triglycerides, free fatty acids (FFA), С-reactive protein (CRP), blood glucose levels were examined; interleukin-6 (IL-6), plasminogen activator inhibitor 1 (PAI-1), insulin, С-peptide, leptin, resistin, adiponectin concentrations were evaluated. For the IR diagnosis purposes, HOMA-IR index was evaluated. Results. In the course of atorvastatin thyroglobulin, VLDL cholesterol, HDL cholesterol and Apo-В concentration reduction was noted, FFA, CRP, IL-6, glucose, PAI-1 levels decreased. 12‑day therapy, especially in atorvastatin group, promoted expressed decrease of plasma leptin levels, significant increase of adiponectin concentrations and adiponectin / leptin index. Conclusion. Results of the atorvastatin therapy 20 mg / day are evident in the early recovery period and, most probably are caused by pleiotropic effect. In addition to hypolipidemic and antiinflammatory effects, atorvastatin promotes reduction of IR manifestation, restoration adipokin status, which increases MI patients treatment effectiveness and improves prognosis after discharge.
  1. Оганов Р. Г., Масленникова Г. Я. Демографическая ситуация и сердечно-сосудистые заболевания в России: пути решения проблем. Кардиоваскулярная терапия и профилактика. 2007;6 (8):7–14.
  2. Rosamond W, Flegal K, Furie K et al. Heart Disease and Stroke Statistics 2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117 (4):e25–146.
  3. Кремнева Л. В., Шалаев С. В. Гипергликемия у больных острым коронарным синдромом. Атеротромбоз. 2009;2 (1):86–94.
  4. Аронов Д. М. Каскад терапевтических эффектов статинов. Кардиология. 2004;42 (10):85–94.
  5. Краснокутский С. В., Кочуев Г. И., Дяченко И. В. и др. Ранние липидные и плеотропные эффекты аторвастатина у больных стабильной стенокардией с гиперхолестеринемией. Вісник Сумського державного університету. Серія Медицина. 2006;86 (2):131–138.
  6. Gotto AM, Whitney E, Stein EA et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force / Texas Coronary Atherosclerosis Prevention Study (AFCAPS / TexCAPS). Circulation. 2000;101 (5):477–484.
  7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.. N Engl J Med. 1998;339 (19):1349–1357.
  8. Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344 (8934):1383–1389.
  9. Rodríguez-Calvo R, Barroso E, Serrano L et al. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology. 2009;49 (1):106–115.
  10. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1 – associated phosphatidylinositol 3‑kinase activity. J Clin Invest. 1999;103 (2):253–259.
  11. Митченко Е. И., Романов В. Ю. Исследование гиполипидемической эффективности, безопасности и влияния на инсулинорезистентность терапии аторвастатином у больных ИБС и сахарным диабетом типа 2. Consilium medicum ukraina. 2010;4 (5):12–14.
  12. Мычка В. Б., Чазова И. Е. Влияние гиполипидемической терапии на инсулинорезистентность у пациентов с метаболическим синдромом. Consilium-medicum. 2004;6 (1):7–10.
  13. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008;52 (15):1201–1210.
  14. Wallander M, Söderberg S, Norhammar A. Leptin: a predictor of abnormal glucose tolerance and prognosis in patients with myocardial infarction and without previously known Type 2 diabetes. Diabet Med. 2008;25 (8):949–955.
  15. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302 (2):179–188.
  16. Gupta A, Badyal DK, Khosla PP et al. Effect of atorvastatin on hs‑CRP in acute coronary syndrome. Br J Clin Pharmacol. 2008;66 (3):411–413.
  17. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: the links, causes and consequences. Arterioscler Thromb Vasc Biol. 2006;26 (10):2200–2207.
Silonova A. A., Barbarash O. L., Akbasheva O. E. et al. Influence of atorvastatin on lipid transport function of blood, markers of insulin resistance and inflammation indices in patients with myocardial infarction in dynamics during hospitalisation. Russian Heart Journal. 2012;11(6):330-336.

To access this material please log in or register

Register Authorize
Ru En